Aligos Therapeutics (NASDAQ:ALGS) Now Covered by Analysts at Jefferies Financial Group

Posted by George Bondi on Nov 10th, 2026

Jefferies Financial Group started coverage on shares of Aligos Therapeutics (NASDAQ:ALGS – Free Report) in a research note released on Monday,Zacks reports. The brokerage issued a strong-buy rating on the stock.

ALGS has been the topic of a number of other reports. Weiss Ratings lowered Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. HC Wainwright reaffirmed a “buy” rating on shares of Aligos Therapeutics in a research report on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.50.

View Our Latest Analysis on Aligos Therapeutics

Aligos Therapeutics Stock Performance

Aligos Therapeutics stock opened at $3.95 on Monday. Aligos Therapeutics has a fifty-two week low of $3.95 and a fifty-two week high of $13.69. The firm’s 50-day simple moving average is $5.25 and its 200 day simple moving average is $6.15. The stock has a market cap of $24.65 million, a PE ratio of -0.62 and a beta of 2.43.

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last posted its earnings results on Friday, November 6th. The company reported ($2.09) EPS for the quarter, topping the consensus estimate of ($2.28) by $0.19. The firm had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $4.85 million. Aligos Therapeutics had a negative net margin of 241.01% and a negative return on equity of 160.72%. As a group, analysts predict that Aligos Therapeutics will post -6.81 EPS for the current fiscal year.

Institutional Investors Weigh In On Aligos Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALGS. SummitTX Capital L.P. raised its stake in shares of Aligos Therapeutics by 6.7% during the first quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock worth $1,106,000 after acquiring an additional 9,375 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Aligos Therapeutics by 17.6% in the first quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock valued at $746,000 after acquiring an additional 15,006 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Aligos Therapeutics by 1,652.8% during the 1st quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock valued at $1,707,000 after purchasing an additional 216,646 shares in the last quarter. 60.43% of the stock is currently owned by institutional investors.

About Aligos Therapeutics

(Get Free Report)

Aligos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for viral infections and liver diseases. The company’s research programs are designed to address conditions with significant unmet medical needs, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and selected respiratory viral infections.

Aligos’ pipeline has included investigational therapies such as ALG-000184, an oral capsid assembly modulator being developed for chronic HBV, and ALG-055009, an oral thyroid hormone receptor beta agonist under evaluation for MASH.